Works matching AU Garcia-Manero G

Results: 83
    1
    2
    3
    4
    5

    P1052: IMPACT OF SF3B1 MUTATION IN MYELOFIBROSIS.

    Published in:
    HemaSphere, 2022, v. 6, p. 942, doi. 10.1097/01.HS9.0000847076.55141.3b
    By:
    • Senapati, J.;
    • Verstovsek, S.;
    • Masarova, L.;
    • Pemmaraju, N.;
    • Montalban Bravo, G.;
    • Pierce, S.;
    • Zhou, L.;
    • Garcia‐Manero, G.;
    • Kantarjian, H.;
    • Bose, P.
    Publication type:
    Article
    6

    P784: A PHASE I/II STUDY OF VENETOCLAX IN COMBINATION WITH ASTX727 (DECITABINE/CEDAZURIDINE) IN TREATMENT‐NAÏVE HIGH‐RISK MYELODYSPLASTIC SYNDROME (MDS) OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

    Published in:
    HemaSphere, 2022, v. 6, p. 679, doi. 10.1097/01.HS9.0000846020.01506.f5
    By:
    • Venugopal, S.;
    • kantarjian, H.;
    • Maiti, A.;
    • Short, N.;
    • Montalban‐Bravo, G.;
    • Alvarado, Y.;
    • Chien, K. S.;
    • Kanagal‐Shamanna, R.;
    • Pemmaraju, N.;
    • Daver, N.;
    • Kadia, T.;
    • Borthakur, G.;
    • Jabbour, E.;
    • Garcia‐Manero, G.
    Publication type:
    Article
    7
    8
    9
    10
    11
    12
    13
    14

    P765: UPDATED ENROLLMENT AND RESULTS FROM THE PHASE 1 SUBSTUDY OF IVOSIDENIB IN PATIENTS WITH IDH1‐MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME (R/R MDS)

    Published in:
    HemaSphere, 2022, v. 6, p. 660, doi. 10.1097/01.HS9.0000845944.18977.d1
    By:
    • DiNardo, C. D.;
    • Foran, J. M.;
    • Watts, J. M.;
    • Stein, E. M.;
    • de Botton, S.;
    • Fathi, A. T.;
    • Prince, G. T.;
    • Stone, R. M.;
    • Patel, P. A.;
    • Roboz, G. J.;
    • Arellano, M. L.;
    • Erba, H. P.;
    • Pigneux, A.;
    • Baratam, P.;
    • Stuart, R. K.;
    • Thomas, X.;
    • Lemieux, I. R.;
    • Bai, X.;
    • Kapsalis, S. M.;
    • Garcia‐Manero, G.
    Publication type:
    Article
    15
    16
    17
    18
    19
    20

    P581: PHASE II STUDY OF LOWER‐INTENSITY FRONTLINE THERAPY FOR NEWLY DIAGNOSED PATIENTS WITH AML WHO ARE UNFIT OR OTHERWISE NOT ELIGIBLE FOR FRONTLINE CLINICAL TRIALS.

    Published in:
    HemaSphere, 2022, v. 6, p. 480, doi. 10.1097/01.HS9.0000845212.90937.74
    By:
    • Venugopal, S.;
    • Jabbour, E.;
    • Pemmaraju, N.;
    • Montalban‐Bravo, G.;
    • Chien, K. S.;
    • Daver, N.;
    • Jain, N.;
    • Burger, J.;
    • Alvarado, Y.;
    • Maiti, A.;
    • DiNardo, C. D.;
    • Borthakur, G.;
    • Malla, R.;
    • Garcia‐Manero, G.;
    • Ravandi, F.;
    • Kantarjian, H.;
    • Kadia, T.
    Publication type:
    Article
    21
    22

    P566: IMPACT OF FRONTLINE INDUCTION APPROACH ON POST‐STEM CELL TRANSPLANT (SCT) OUTCOMES IN OLDER ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)

    Published in:
    HemaSphere, 2022, v. 6, p. 465, doi. 10.1097/01.HS9.0000845152.83025.17
    By:
    • Ong, F.;
    • Ravandi, F.;
    • Popat, U.;
    • Kadia, T. M.;
    • Daver, N.;
    • DiNardo, C.;
    • Konopleva, M.;
    • Borthakur, G.;
    • Shpall, E. J.;
    • Oran, B.;
    • Al‐Atrash, G.;
    • Mehta, R.;
    • Jabbour, E. J.;
    • Yilmaz, M.;
    • Issa, G. C.;
    • Garcia‐Manero, G.;
    • Maiti, A.;
    • Abbas, H. A.;
    • Champlin, R. E.;
    • Short, N. J.
    Publication type:
    Article
    23
    24
    25

    P495: PHASE 2 STUDY OF ASTX727 (DECITABINE/CEDAZURIDINE) PLUS VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) OR PREVIOUSLY UNTREATED, ELDERLY PATIENTS UNFIT FOR CHEMOTHERAPY.

    Published in:
    HemaSphere, 2022, v. 6, p. 394, doi. 10.1097/01.HS9.0000844868.29082.72
    By:
    • Abuasab, T.;
    • Alvarado, Y.;
    • Issa, G.;
    • Islam, R.;
    • Short, N.;
    • Yilmaz, M.;
    • jain, N.;
    • Masarova, L.;
    • Kornblau, S.;
    • Jabbour, E.;
    • Pemmaraju, N.;
    • Montalban‐Bravo, G.;
    • Pierce, S.;
    • DiNardo, C.;
    • Kadia, T.;
    • Daver, N.;
    • Konopleva, M.;
    • Garcia‐Manero, G.;
    • Ravandi, F.
    Publication type:
    Article
    26

    P369: A PHASE II STUDY OF MINI‐HYPER‐CVD PLUS VENETOCLAX IN PATIENTS WITH PHILADELPHIA CHROMOSOME‐NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA.

    Published in:
    HemaSphere, 2022, v. 6, p. 269, doi. 10.1097/01.HS9.0000844364.76062.09
    By:
    • Senapati, J.;
    • Kantarjian, H.;
    • Short, N.;
    • Konopleva, M.;
    • Ravandi, F.;
    • Jain, N.;
    • Thompson, P. A.;
    • Pemmaraju, N.;
    • Wierda, W. G.;
    • Borthakur, G.;
    • Kadia, T. M.;
    • Garcia‐Manero, G.;
    • Yilmaz, M.;
    • Thankachan, J.;
    • Zhao, M.;
    • Loiselle, C.;
    • Talley, M. T.;
    • Kwari, M. I.;
    • Garris, R. S.;
    • Jabbour, E. J.
    Publication type:
    Article
    27

    P365: INCORPORATION OF NELARABINE (NEL), PEGYLATED ASPARAGINASE (PEG) AND VENETOCLAX (VEN) IN THE FRONTLINE THERAPY OF ADULT PATIENTS WITH T‐ACUTE LYMPHOBLASTIC LEUKEMIA/T‐LYMPHOBLASTIC LYMPHOMA (T‐ALL/LBL)

    Published in:
    HemaSphere, 2022, v. 6, p. 265, doi. 10.1097/01.HS9.0000844348.09845.a2
    By:
    • Ravandi, F.;
    • Jabbour, E.;
    • Jain, N.;
    • Kadia, T.;
    • Gautam, B.;
    • Konopleva, M.;
    • Wierda, W.;
    • Burger, J.;
    • Issa, G.;
    • Maiti, A.;
    • Balkin, H.;
    • Kelly, M.;
    • Garris, R.;
    • Kebriaei, P.;
    • Ferrajoli, A.;
    • Garcia‐Manero, G.;
    • Alvarado, Y.;
    • Short, N.;
    • Kantarjian, H.
    Publication type:
    Article
    28

    S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER‐RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS.

    Published in:
    HemaSphere, 2022, v. 6, p. 67, doi. 10.1097/01.HS9.0000843556.59348.1d
    By:
    • Sallman, D. A.;
    • Al Malki, M. M.;
    • Asch, A. S.;
    • Wang, E. S.;
    • Jurcic, J. G.;
    • Bradley, T. J.;
    • Flinn, I. W.;
    • Pollyea, D. A.;
    • Kambhampati, S. N.;
    • Tanaka, T. N.;
    • Zeidner, J. F.;
    • Garcia‐Manero, G.;
    • Jeyakumar, D.;
    • Gu, L.;
    • Tan, A.;
    • Chao, M.;
    • O'Hear, C.;
    • Lal, I.;
    • Vyas, P.;
    • Daver, N.
    Publication type:
    Article
    29
    30

    S129: TAKEAIM LEUKEMIA‐ A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA‐4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS.

    Published in:
    HemaSphere, 2022, v. 6, p. 30, doi. 10.1097/01.HS9.0000843408.31385.3f
    By:
    • Garcia‐Manero, G.;
    • Winer, E. S.;
    • DeAngelo, D. J.;
    • Tarantolo, S.;
    • Sallman, D. A.;
    • Dugan, J.;
    • Groepper, S.;
    • Giagounidis, A.;
    • Götze, K.;
    • Metzeler, K. H.;
    • Li, C.‐C.;
    • Zhou, L.;
    • Martinez, E.;
    • Lane, M.;
    • von Roemeling, R.;
    • Bohme, M.;
    • Kubasch, A. S.;
    • Verma, A.;
    • Platzbecker, U.
    Publication type:
    Article
    31

    S127: QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS ACTIVE IN PATIENTS WITH FLT3‐ITD MUTATED ACUTE MYELOID LEUKEMIA ‐ A PHASE I/II STUDY.

    Published in:
    HemaSphere, 2022, v. 6, p. 28, doi. 10.1097/01.HS9.0000843400.36721.1d
    By:
    • Yilmaz, M.;
    • Muftuoglu, M.;
    • Kantarjian, H.;
    • DiNardo, C.;
    • Kadia, T.;
    • Borthakur, G.;
    • Pemmaraju, N.;
    • Short, N.;
    • Alvarado, Y.;
    • Maiti, A.;
    • Masarova, L.;
    • Montalban Bravo, G.;
    • Loghavi, S.;
    • Patel, K.;
    • Kornblau, S.;
    • Jabbour, E.;
    • Garcia‐Manero, G.;
    • Andreeff, M.;
    • Daver, N.
    Publication type:
    Article
    32

    S114: PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH PHILADELPHIA CHROMOSOME‐POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE II STUDY.

    Published in:
    HemaSphere, 2022, v. 6, p. 15, doi. 10.1097/01.HS9.0000843352.55138.40
    By:
    • Short, N.;
    • Kantarjian, H.;
    • Konopleva, M.;
    • Jain, N.;
    • Ravandi, F.;
    • Huang, X.;
    • Macaron, W.;
    • Wierda, W.;
    • Borthakur, G.;
    • Kadia, T.;
    • Sasaki, K.;
    • Issa, G.;
    • Montalban‐Bravo, G.;
    • Alvarado, Y.;
    • Garcia‐Manero, G.;
    • Dinardo, C.;
    • Thankachan, J.;
    • Delumpa, R.;
    • Mayor, E.;
    • Deen, W.
    Publication type:
    Article
    33
    34
    35
    36
    37
    38
    39
    40

    Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor.

    Published in:
    2011
    By:
    • Cortes J;
    • Quintás-Cardama A;
    • Jones D;
    • Ravandi F;
    • Garcia-Manero G;
    • Verstovsek S;
    • Koller C;
    • Hiteshew J;
    • Shan J;
    • O'Brien S;
    • Kantarjian H;
    • Cortes, Jorge;
    • Quintás-Cardama, Alfonso;
    • Jones, Dan;
    • Ravandi, Farhad;
    • Garcia-Manero, Guillermo;
    • Verstovsek, Srdan;
    • Koller, Charles;
    • Hiteshew, Jody;
    • Shan, Jenny
    Publication type:
    journal article
    41

    Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

    Published in:
    2010
    By:
    • de Lima M;
    • Giralt S;
    • Thall PF;
    • de Padua Silva L;
    • Jones RB;
    • Komanduri K;
    • Braun TM;
    • Nguyen HQ;
    • Champlin R;
    • Garcia-Manero G;
    • de Lima, Marcos;
    • Giralt, Sergio;
    • Thall, Peter F;
    • de Padua Silva, Leandro;
    • Jones, Roy B;
    • Komanduri, Krishna;
    • Braun, Thomas M;
    • Nguyen, Hoang Q;
    • Champlin, Richard;
    • Garcia-Manero, Guillermo
    Publication type:
    journal article
    42
    43
    44
    45

    Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)

    Published in:
    Leukemia (08876924), 2015, v. 29, n. 7, p. 1502, doi. 10.1038/leu.2015.55
    By:
    • Della Porta, M G;
    • Tuechler, H;
    • Malcovati, L;
    • Schanz, J;
    • Sanz, G;
    • Garcia-Manero, G;
    • Solé, F;
    • Bennett, J M;
    • Bowen, D;
    • Fenaux, P;
    • Dreyfus, F;
    • Kantarjian, H;
    • Kuendgen, A;
    • Levis, A;
    • Cermak, J;
    • Fonatsch, C;
    • Le Beau, M M;
    • Slovak, M L;
    • Krieger, O;
    • Luebbert, M
    Publication type:
    Article
    46
    47
    48
    49
    50